Suzuken Q1 Operating Profit Falls 25% as Purchase Prices and Distribution Costs Outrun 6.1% Sales Growth

Sales grew 6.1%, gross profit 0.2% — the margin gave way underneath

Suzuken Co., Ltd. (TSE: 9987), the pharmaceutical group whose core business is the wholesale distribution of prescription drugs, published consolidated results for the first quarter of FY3/2027, the three months from April 1 to June 30, 2026, on August 7, 2026 under Japanese GAAP. Revenue rose 6.1% to ¥628,962 million, operating profit fell 25.0% to ¥4,190 million, ordinary profit fell 12.3% to ¥5,074 million and profit attributable to owners of the parent fell 10.6% to ¥3,381 million, or ¥49.99 per share against ¥52.63. The shares are listed on the Tokyo, Nagoya and Sapporo stock exchanges.

The arithmetic is short. Cost of sales rose 6.6% to ¥585,612 million, a shade faster than revenue, so gross profit edged up only 0.2% to ¥43,349 million and the gross margin narrowed from 7.3% to 6.9%. Selling, general and administrative expenses rose 3.9% to ¥39,158 million — well below the rate of sales growth, but on a gross profit that did not grow, every extra yen of cost came straight off the operating line. Operating profit fell by ¥1,396 million to ¥4,190 million, and the operating margin slipped from 0.94% to 0.67%. In a business that keeps less than one yen of operating profit from every ¥100 of sales, a 0.4-point move in the gross margin is enough to take a quarter off operating profit.

The company names purchase prices and inflation as the causes

The filing is explicit about why. Sales grew because the prescription-drug market expanded and new drugs, including specialty pharmaceuticals, contributed. The company says it kept pursuing appropriate margins and reviewing and restraining SG&A, but higher purchase prices for pharmaceuticals and increased operating costs stemming from inflation, such as outsourcing expenses, pushed operating profit down. It also discloses that selling prices had not yet been settled with customers representing just under 90% of the total, and that sales to them have been booked at estimated prices reflecting the price levels those customers are asking for — so part of the quarter's margin rests on an estimate that later negotiations will settle.

Below the operating line, an equity-method swing softened the fall

Ordinary profit fell less steeply than operating profit, by 12.3% to ¥5,074 million, because non-operating items moved in Suzuken's favour. Non-operating income rose to ¥991 million from ¥744 million, including an equity-method investment gain of ¥248 million, while non-operating expenses dropped to ¥107 million from ¥547 million, chiefly because the prior year's ¥439 million equity-method loss did not recur; dividends received fell to ¥284 million from ¥447 million. Extraordinary gains were only ¥68 million against ¥528 million a year earlier, most of which was an item the filing labels simply as other, so pre-tax profit fell 18.5% to ¥5,121 million. Income taxes dropped to ¥1,732 million from ¥2,501 million, which is why net profit fell by only 10.6%. Earnings per share fell less again, by 5.0% to ¥49.99, because the average number of shares outstanding was 67.64 million against 71.86 million a year earlier.

Wholesale carried the sales; five of six segments earned less or lost money

Suzuken reorganised its reporting this quarter under a new medium-term plan running to FY3/2029, moving from five segments to six and folding its specialty-pharmaceutical distribution business into pharmaceutical wholesale; prior-year figures have been restated on the new basis, and segment revenues include intersegment sales. Pharmaceutical Wholesale, by far the largest, grew revenue 6.3% to ¥607,825 million on the market's growth and new specialty drugs, but its segment profit fell 11.0% to ¥3,528 million, which the company attributes to higher purchase prices and rising drug-distribution costs, starting with logistics outsourcing. Logistics was the one segment to earn more: revenue rose 2.9% to ¥14,476 million on revised contract prices in wholesale logistics and higher volumes in logistics for manufacturers, and profit rose 24.7% to ¥943 million on continued productivity gains.

Elsewhere the quarter was weaker. Healthcare Product Development, which includes the group's drug and medical-device manufacturing, grew revenue 2.1% to ¥12,934 million as Upasita, a syringe product for secondary hyperparathyroidism in dialysis patients, and a darbepoetin alfa biosimilar offset NHI price cuts, but profit fell 65.8% to ¥292 million on a lower gross margin after the price revision and higher research and development spending on Paltusotine, an oral treatment for acromegaly. Regional Medical and Care Support, which includes dispensing pharmacies, saw revenue slip 1.7% to ¥22,719 million as longer prescription periods and pharmacy closures cut the number of prescriptions received, and swung to a segment loss of ¥229 million from a ¥22 million profit. Digital Business grew revenue 33.4% to ¥808 million but widened its loss to ¥329 million from ¥45 million on upfront investment in new services, and Other Related earned ¥22 million, down 43.2%, on revenue of ¥1,363 million.

Working capital swelled the balance sheet

Total assets rose 3.5% to ¥1,195,684 million from ¥1,155,766 million at March 31, 2026, almost entirely in current assets: notes and accounts receivable rose by ¥27,054 million, merchandise and finished goods by ¥9,044 million and cash and deposits by ¥4,726 million. On the other side, notes and accounts payable rose by ¥34,860 million and other current liabilities by ¥19,248 million, while income taxes payable fell by ¥8,208 million and the bonus provision by ¥5,692 million. Net assets were essentially unchanged at ¥415,888 million: the quarter's ¥3,381 million of net profit was matched by ¥3,381 million of dividends paid. With the balance sheet larger and equity flat, the equity ratio fell from 36.0% to 34.8%.

Guidance kept, with a two-for-one split and a higher dividend ahead

Suzuken did not change the forecasts it published on May 14, 2026. For FY3/2027 it expects revenue of ¥2,563,000 million (+3.1%), operating profit of ¥31,200 million (−14.2%), ordinary profit of ¥34,300 million (−13.7%) and profit attributable to owners of ¥25,000 million (−34.4%). For the first half it guides operating profit of ¥11,900 million, down 29.8%. The first quarter delivered 24.5% of the full-year revenue forecast but only 13.4% of the operating-profit forecast and 35.2% of the first-half figure, which leaves an implied ¥7,710 million of operating profit for the second quarter alone. The filing does not explain that phasing.

The company will split each share into two with effect from October 1, 2026, with a record date of September 30. Before the split, the dividend forecast is ¥120 for the year against ¥100 for FY3/2026: ¥60 at the interim and ¥60 at the year-end, the latter shown in the filing as ¥30 on the post-split basis. Forecast full-year earnings per share are ¥184.81 after the split, or ¥369.62 without it. Under a shareholder-return policy announced in May 2026, Suzuken uses a total return ratio of 100% as its benchmark, delivered through dividends and flexible share buybacks, and aims to raise its dividend-on-equity ratio step by step to around 3% by FY3/2029.

An earthquake has halted a subsidiary's plant

After the quarter closed, the Kumamoto earthquake of July 28, 2026 damaged parts of the buildings and manufacturing equipment at the Kumamoto plant of drug-manufacturing subsidiary Sanwa Kagaku Kenkyusho in Uto City, and the plant has suspended operations. The company says inventories of the plant's products are secured and that it expects to avoid any immediate supply disruption, but the timing of a restart is still under investigation. All employees at the affected subsidiaries are confirmed safe, no serious damage was found at other subsidiaries, and the effect on full-year results is still being assessed; the guidance was left unchanged while that work continues.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.